[{"indications": "Indications\u00a0chronic severe spasticity of voluntary muscle;\r\nmalignant hyperthermia (section 15.1.8)", "name": "DANTROLENE SODIUM", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "10 Musculoskeletal and joint diseases", "10.2 Drugs used in neuromuscular disorders", "10.2.2 Skeletal muscle relaxants"], "cautions": "Cautions\u00a0impaired cardiac and pulmonary function; therapeutic effect may take a few weeks to develop\u2014discontinue\r\nif no response within 6\u20138 weeks; interactions: Appendix 1 (muscle relaxants).Hepatotoxicity\u00a0Potentially life-threatening\r\nhepatotoxicity reported, usually if doses greater than 400\u00a0mg daily\r\nused, in females, patients over 30 years, if history of liver disorders,\r\nor concomitant use of hepatotoxic drugs; test liver function before and at intervals during therapy\u2014discontinue if abnormal liver function tests or symptoms of liver\r\ndisorder (counselling, see below); re-introduce only if complete reversal\r\nof hepatotoxicityCounselling\u00a0Patients should be told\r\nhow to recognise signs of liver disorder and advised to seek prompt\r\nmedical attention if symptoms such as anorexia, nausea, vomiting,\r\nfatigue, abdominal pain, dark urine, or pruritus developDriving\u00a0Drowsiness may affect performance\r\nof skilled tasks (e.g. driving); effects\r\nof alcohol enhanced", "side-effects": "Side-effects\u00a0diarrhoea (withdraw if severe, discontinue treatment\r\nif recurs on re-introduction), nausea, vomiting, anorexia, hepatotoxicity\r\n(see above), abdominal pain; pericarditis; pleural effusion, respiratory\r\ndepression; headache, drowsiness, dizziness, asthenia, fatigue, seizures,\r\nfever, chills; speech and visual disturbances; rash; less\r\ncommonly dysphagia, constipation, exacerbation of cardiac\r\ninsufficiency, tachycardia, erratic blood pressure, dyspnoea, depression,\r\nconfusion, nervousness, insomnia, increased urinary frequency, urinary\r\nincontinence or retention, haematuria, crystalluria, and increased\r\nsweating", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5338.htm", "doses": ["Initially 25\u00a0mg daily, may be increased at weekly intervals\r\nto max. 100\u00a0mg 4 times daily; usual dose 75\u00a0mg 3 times daily; child 5\u201318 years see BNF for Children"], "pregnancy": "Pregnancy\u00a0avoid use in chronic spasticity\u2014embryotoxic in animal studies"}, {"indications": "Indications\u00a0malignant hyperthermia; chronic\r\nsevere spasticity of voluntary muscle (section 10.2.2)", "name": "DANTROLENE SODIUM - DRUGS FOR MALIGNANT HYPERTHERMIA", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "15 Anaesthesia", "15.1 General anaesthesia", "15.1.8 Drugs for malignant hyperthermia", "DANTROLENE SODIUM"], "cautions": "Cautions\u00a0avoid extravasation (risk of tissue necrosis); interactions: Appendix 1 (muscle relaxants)", "side-effects": "Side-effects\u00a0hepatotoxicity, pulmonary oedema, dizziness, weakness,\r\nand injection-site reactions including erythema, rash, swelling, and\r\nthrombophlebitis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/6683.htm", "doses": ["By rapid intravenous injection, adult, initially 2\u20133\u00a0mg/kg, then 1\u00a0mg/kg repeated\r\nas required to a cumulative max. of 10\u00a0mg/kg; child 1 month\u201318 years see BNF for Children"], "pregnancy": "Pregnancy\u00a0use only if potential benefit outweighs risk"}, {"indications": "Indications\u00a0chronic severe spasticity of voluntary muscle;\r\nmalignant hyperthermia (section 15.1.8)", "name": "DANTROLENE SODIUM - SKELETAL MUSCLE RELAXANTS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "10 Musculoskeletal and joint diseases", "10.2 Drugs used in neuromuscular disorders", "10.2.2 Skeletal muscle relaxants"], "cautions": "Cautions\u00a0impaired cardiac and pulmonary function; therapeutic effect may take a few weeks to develop\u2014discontinue\r\nif no response within 6\u20138 weeks; interactions: Appendix 1 (muscle relaxants).Hepatotoxicity\u00a0Potentially life-threatening\r\nhepatotoxicity reported, usually if doses greater than 400\u00a0mg daily\r\nused, in females, patients over 30 years, if history of liver disorders,\r\nor concomitant use of hepatotoxic drugs; test liver function before and at intervals during therapy\u2014discontinue if abnormal liver function tests or symptoms of liver\r\ndisorder (counselling, see below); re-introduce only if complete reversal\r\nof hepatotoxicityCounselling\u00a0Patients should be told\r\nhow to recognise signs of liver disorder and advised to seek prompt\r\nmedical attention if symptoms such as anorexia, nausea, vomiting,\r\nfatigue, abdominal pain, dark urine, or pruritus developDriving\u00a0Drowsiness may affect performance\r\nof skilled tasks (e.g. driving); effects\r\nof alcohol enhanced", "side-effects": "Side-effects\u00a0diarrhoea (withdraw if severe, discontinue treatment\r\nif recurs on re-introduction), nausea, vomiting, anorexia, hepatotoxicity\r\n(see above), abdominal pain; pericarditis; pleural effusion, respiratory\r\ndepression; headache, drowsiness, dizziness, asthenia, fatigue, seizures,\r\nfever, chills; speech and visual disturbances; rash; less\r\ncommonly dysphagia, constipation, exacerbation of cardiac\r\ninsufficiency, tachycardia, erratic blood pressure, dyspnoea, depression,\r\nconfusion, nervousness, insomnia, increased urinary frequency, urinary\r\nincontinence or retention, haematuria, crystalluria, and increased\r\nsweating", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5338.htm", "doses": ["Initially 25\u00a0mg daily, may be increased at weekly intervals\r\nto max. 100\u00a0mg 4 times daily; usual dose 75\u00a0mg 3 times daily; child 5\u201318 years see BNF for Children"], "pregnancy": "Pregnancy\u00a0avoid use in chronic spasticity\u2014embryotoxic in animal studies"}]